The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS)

Reproductive Toxicology

Volumn 10, Issue 4, 1996, Pages 285-294

  McElhatton, Patricia R ^a   Garbis, Hanneke M ^b   Eléfant, Elisabeth ^c   Vial, Thierry ^d   Bellemin, Béatrice ^e   Mastroiacovo, Pierpaolo ^f   Arnon, Judith ^g   Rodríguez Pinilla, Elvira ^h   Schaefer, Christof ⁱ   Pexieder, Tomas ^j   Merlob, Paul ^k   Dal Verme, Sabina ^l  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c HÔPITAL SAINT ANTOINE   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e Institut Europeen des Genomutations   (France)

^f CATHOLIC UNIVERSITY   (Italy)

^g HEBREW UNIVERSITY   (Israel)

^h TELEFONICA RESEARCH   (Spain)

ⁱ Vergiftungserscheinungen   (Germany)

^j UNIVERSITY OF LAUSANNE   (Switzerland)

^k RABIN MEDICAL CENTER   (Israel)

^l SAN PAOLO HOSPITAL   (Italy)

more..

Author keywords

antidepressants; pregnancy outcome; prospective follow up study

Indexed keywords

EID: 0030197563     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/0890-6238(96)00057-3     Document Type: Article

References (49)

1. 1. Robson JM, Sullivan FM. The production of foetal abnormalities in rabbits with imipramine. Lancet. 1963;1:638-9.
2. 2. Harper KH, Palmer AK, Davies RE. Effect of imipramine upon the pregnancy of laboratory animals. Arzneimittelforschung. 1965;15: 1218-21.
3. 3. Hendrickx AG. Teratologic evaluation of imipramine hydrochloride in bonnet (Macaca radiata) and rhesus monkeys (Macaca mulatto). Teratology. 1975;11:219-21.
4. 4. Geber WF, Gill TS, Guram MS. Comparative teratogenicity of chlordiazepoxide, diazepam, amitriptyline and imipramine in the foetal hamster. Teratology. 1980;21:39A.
5. 5. Guram MS, Gill TS, Geber WF. Comparative teratogenicity of chlordiazepoxide, amitriptyline and a combination of the two compounds in the fetal hamster. Neurotoxicology. 1982;3:83-90.
6. 6. Beyer BK, Guram MS, Geber WF. Incidence and potentiation of external and internal fetal anomalies from chlordiazepoxide and amitriptyline alone and in combination. Teratology. 1984;30:39-45.
7. 7. Banister P, Dafoe C, Smith ESO, Miller J. Possible teratogenicity of tricyclic antidepressants. Lancet. 1972;1:838-9.
8. 8. Barson AJ. Malformed infant. Br Med J. 1972;2:45.
9. 9. Freeman R. Limb deformities: Possible association with drugs. Med J Aust. 1972;1:606-7.
10. 10. Kuenssberg EV, Knox JD. Imipramine in pregnancy. Br Med J. 1972;2:292.
11. 11. McBride WG. Limb deformities associated with iminodibenzyl hydrochloride. Med J Aust. 1972;1:492.
12. 12. Idänpään-Heikkilä J, Saxén L. Possible teratogenicity of imipramine/chloropyramine. Lancet. 1973;2:282-4.
13. 13. Galan Rubi F, Laguardia Garcia G, Zabadski P, et al. A case of acranial pregnancy in a psychiatric patient under amitriptyline treatment. Revista Hospital Psiquiatrico Habana. 1978;19:635-43.
14. 14. Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol. 1981;58:336-44.
15. 15. Crombie DL, Pinsent RJFH, Fleming D. Imipramine in pregnancy. Br Med J. 1972;1:745.
16. 16. Levy L. Imipramine and fetal deformities. Can Med Assoc J. 1972; 106:1057-8.
17. 17. Rachelefsky GS, Flynt JW, Ebbin AJ, et al. Possible teratogenicity of tricyclic antidepressants. Lancet. 1972;1:838-9.
18. 18. Sim M. Imipramine and pregnancy. Br Med J. 1972;2:45.
19. 19. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton: Publishing Sciences Group; 1977.
20. 20. Bourke GM. Antidepressant teratogenicity. Lancet. 1974;1:98.
21. 21. Abramovici A, Abramovici I, Kalman G, Liban E. Teratogenic effect of chlorimipramine in a young human embryo. Teratology. 1981;24:42A.
22. 22. Chambers CD, Johnson KA, Jones KL. Pregnancy outcome in women exposed to fluoxetine. Reprod Toxicol. 1993;7:155-6.
23. 23. Goldstein DJ, Marvel DE. Psychotropic medications during pregnancy: risk to the fetus. JAMA. 1993;270:2177.
24. 24. Patuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-8.
25. 25. Eggermont E, Raveschot J, Deneve V, Casteels-Vandaele M. The adverse influence of imipramine on the adaptation of the newborn infant to extrauterine life. Acta Paediatr Belg. 1972;26:197-204.
26. 26. Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr. 1972;81:570-572.
27. 27. Sjöquist F, Bergfors PG, Borga O, et al. Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: evidence for drug metabolism. J Pediatr. 1972;80:496-500.
28. 28. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet. 1973;2:318-9.
29. 29. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J. 1982;284: 1837-38.
30. 30. Zahle Oestergaard G, Pedersen SE. Neonatal effects of maternal clomipramine treatment. Pediatrics. 1982;69:233-4.
31. 31. Prentice A, Brown R. Fetal tachyarrhythmia and maternal antidepressant treatment. Br Med J. 1989;298:190.
32. 32. Singh S, Gulati S, Narang A, Bhakoo ON. Nonnarcotic withdrawal syndrome in a neonate due to maternal clomipramine therapy. J Paediatr Child Health. 1990;26:110.
33. 33. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatr Med. 1991;21:157-71.
34. 34. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. Clin Toxicol. 1991;29: 479-84.
35. 35. Bromiker R, Kaplan M. Apparent intrauterine fetal withdrawal from clomipramine hydrochloride. JAMA. 1994;272:1722-3.
36. 36. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993;92:721-2.
37. 37. Garbis JM, Robert E, Peters PWJ. Experience of two Teratology Information Services in Europe. Teratology. 1990;42:629-34.
38. 38. Schaefer C, Vennewald F. FETIS - documentation and follow up program for cooperation between Teratology Information Services. Teratology. 1993;47:435.
39. 39. Eléfant E, Boyer M, Boyer P, et al. Teratogenic agent Information Centre: fifteen years of counseling and pregnancy follow-up. Teratology. 1992;46:35-44.
40. 40. Mastroiacovo P, Serafini MA, Pagano M, et al. The "Telefono Rosso": a service for the prevention of birth defects and for the evaluation of teratogenic risk. Ann. Istit. Superiore Sanità. 1993; 29:115-20.
41. 41. Wigglesworth JS. Monitoring perinatal mortality. A pathophysiologic approach. Lancet. 1980;ii:684-6.
42. 42. Brunel P, Vial T, Roche I, et al. Suivi de 151 grossesses exposées à un traitement antidepresseur (IMAO exclus) au cours de l'organogenèse. Thérapie 1994;49:117-22.
43. 43. Cassady G. The small for date infant. In Avery G, ed. Neonatology, pathophysiology and management of the newborn. 2nd ed. New York: Lippincott; 1981.
44. 44. Wallis SM, Harvey D. Fetal growth, intrauterine growth retardation and small for gestational age babies. In Roberten NRC, ed. Textbook of neonatology. 2nd ed. Edinburgh: Churchill Livingstone; 1992.
45. 45. Reider RO, Rosenthal D, Wender P, Blumenthal H. The offspring of schizophrenics: fetal and neonatal deaths. Arch Gen Psychiatry. 1975;32:200-11.
46. 46. Erlich-Robinson G, Stewart DE, Flak E. The rational use of psychotropic drugs in pregnancy and postpartum. Can J Psychiatry. 1986;31:183-90.
47. 47. Mortola JF. The use of psychotropic agents in pregnancy and lactation. Psychol Clin North Am. 1989;12:69-87.
48. 48. Miller MD. Psychiatric medication during pregnancy: understanding and minimizing risks. Psychiatr Ann. 1994;24:69-75.
49. 49. O'Hara MW, Neunober DJ, Zekoski GH. Prospective study of postpartum depression: prevalence and predictive factors. J Abnorm Psychol. 1981;93:158-71.